Virbac

VIRP

FR0000031577

Pharmaceuticals

Real-time Euronext Paris Other stock markets 10:00:02 2024-04-19 am EDT			5-day change	1st Jan Change
370.5 ^EUR	-0.67%		+1.51%	+3.06%

Apr. 17	VIRBAC : A healthy start to 2024; outlook re-iterated
Apr. 17	Virbac: sales up by almost 10% in Q1	CF

Friulchem S.p.A. entered into a preliminary agreement to acquire BRANCH from Virbac SA for €2.4 million

May 23, 2021

Friulchem S.p.A. (BIT:FCM) entered into a preliminary agreement to acquire a Branch from Virbac SA (ENXTPA:VIRP) for €2.4 million on May 24, 2021. The consideration excludes purchase price of a warehouse which will be defined at closing.

Latest news about Virbac

VIRBAC : A healthy start to 2024; outlook re-iterated	Apr. 17
Virbac: sales up by almost 10% in Q1	Apr. 17	CF
Virbac SA Announces Revenue Results for the First Quarter of 2024	Apr. 16	CI
Virbac: 'strategic' acquisition of Sasaeah in Japan	Apr. 02	CF
Virbac SA acquired Sasaea Holdings Co., Ltd. from ORIX Corporation.	Mar. 31	CI
VIRBAC : Oddo BHF maintains its recommendation on the stock	Mar. 21	CF
CAC40: damage limited despite Kering's fall	Mar. 20	CF
Transcript : Virbac SA, 2023 Earnings Call, Mar 20, 2024	Mar. 20
Virbac: net income unchanged overall in 2023	Mar. 20	CF
Virbac Sa Provides Earnings Guidance for the Year 2024	Mar. 19	CI
Virbac Sa Proposes Dividend for the Year 2023	Mar. 19	CI
Virbac SA Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
CAC40: modest rise, driven by Legrand and Renault	Mar. 06	CF
CAC40: tests 7.960, E-Stoxx50 at its zenith, oil tests $84	Mar. 06	CF
CAC40: back to 7,960, gold sets a new record at $2,144	Mar. 06	CF
CAC40: erases previous day's losses, tops 7950 pts	Mar. 06	CF
Virbac to Buy Orix's Animal Health Unit	Mar. 06	MT
Virbac: acquisition of Sasaeah in Japan	Mar. 06	CF
Virbac SA entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation for an enterprise value of approximately ?280 million.	Mar. 05	CI
Virbac: the Board co-opts Mr. Charmeil as Director	Jan. 25	CF
VIRBAC : Modest beat in Q4; 2024 outlook maintained	Jan. 18
Stifel Keeps Virbac at Hold, Boosts PT	Jan. 18	MT
VIRBAC : Stifel raises its target price	Jan. 18	CF
Virbac: sales up 4.6% in 2023	Jan. 17	CF
Virbac SA Provides Earnings Guidance for the Year 2024	Jan. 17	CI

Chart Virbac

Duration

Period

More charts

Company Profile

Virbac specializes in the research, production and marketing of veterinary medicines. The activity is organized around 2 product families: - pet medications: pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications: pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: France (15.8%), Europe (24.9%), Asia (17.5%), Latin America (16.2%), North America (13.3%), Pacific (9.7%), Africa and Middle East (2.6%).

Sector

Pharmaceuticals

Calendar

2024-06-20 - Annual General Meeting

Related indices

CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

VIRBAC : A healthy start to 2024; outlook re-iterated

April 17, 2024 at 12:39 pm EDT

More Strategies

Ratings for Virbac

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

373 EUR

Average target price

361.6 EUR

Spread / Average Target

-3.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
VIRBAC	+3.06%	3.33B
ELANCO ANIMAL HEALTH INCORPORATED	-10.17%	6.69B
BLUESTAR ADISSEO COMPANY	+13.00%	3.35B
VIMIAN GROUP AB	+2.87%	1.46B
JINYU BIO-TECHNOLOGY CO., LTD.	-17.92%	1.33B
VETOQUINOL SA	-7.13%	1.19B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-28.92%	1.19B
WUHAN KEQIAN BIOLOGY CO.,LTD	-17.76%	1.08B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD.	-3.84%	1.01B
SWEDENCARE AB	-5.51%	868M

Veterinary Drugs

Virbac

Equities

VIRP

FR0000031577

Pharmaceuticals

Friulchem S.p.A. entered into a preliminary agreement to acquire BRANCH from Virbac SA for €2.4 million

EPS Revisions

Quarterly revenue - Rate of surprise